Pediatric Multiple Sclerosis: Diagnosis, Treatment, and Outlook

Multiple Sclerosis in Children

Multiple Sclerosis in Children
Getty Images
Multiple sclerosis (MS) is a condition of the central nervous system (CNS) that can cause muscle weakness and sensory symptoms. It’s usually diagnosed in adults, but children can develop MS too. According to the National Multiple Sclerosis Society (NMSS), fewer than 5,000 children and teens are living with pediatric multiple sclerosis in the United States, and fewer than 10,000 have it worldwide.

As with adults, there’s no way to prevent or cure MS in children. However, many treatments are available to address symptoms for children with the condition. Although MS is a chronic and progressive disease, it isn’t fatal.

Children with MS can maintain a good quality of life well into adulthood by treating and managing the symptoms and associated challenges. 

Here's what you need to know to ensure proper diagnosis and treatment if your child has MS.

Types of Pediatric MS

The three most common types of MS are:

  • Relapsing-Remitting MS (RRMS), in which people experience occasional flare-ups of new or worse symptoms followed by periods of remission, or no symptoms.
  • Secondary-Progressive MS (SPMS) comes after the RRMS stage. In this type, the symptoms and resulting disability gradually progress over time.
  • Primary-Progressive MS (PPMS), in which symptoms are progressive from the onset of the disease.
The vast majority (up to 98 percent) of children with MS have the relapsing-remitting form of the condition; a very small proportion of children develop the primary-progressive type.

Signs and Symptoms of Pediatric MS

In general, most of the symptoms of MS in children are the same as those experienced by adults, namely:

Relapses and Other Signs of Pediatric MS

“Some studies have suggested that children may have up to three times as many relapses as adults early on in the course of their MS,” says E. Ann Yeh, MD, director of the pediatric neuroinflammatory disorders program at the Hospital for Sick Children in Toronto, and a professor of pediatric medicine at the University of Toronto.

As a result, children and adolescents with MS may face challenges in academic performance and family relationships, and the condition can further complicate issues most young people deal with, like poor self-image and making friends.

Although research indicates that MS progresses more slowly in children than in adults, younger people with the condition are more likely to have significant disability earlier after a diagnosis than those with adult-onset MS.

“While it’s true kids generally have more relapses than adults, and they also typically show more inflammation on MRI, as a group the kids recover more fully from relapses than adults,” says Lauren B. Krupp, MD, the director of the NYU Langone Multiple Sclerosis Comprehensive Care Center in New York City.

“As a group, many kids with MS do extremely well. However, children with MS aging into adulthood will reach any disability level generally at a younger age than those with adult-onset MS, so those with pediatric-onset MS may need to use a cane or other assistive devices at a younger age.”

Causes and Risk Factors of Pediatric MS

Researchers don’t yet know what causes pediatric MS. The potential causes and mechanisms are being studied in clinical trials. So far, existing research points to some potential environmental factors that may raise the risk of MS in children, including:

  • Low sunlight exposure or low vitamin D levels
  • Early exposure to Epstein-Barr virus (EBV)
  • Exposure to secondhand smoke
  • Exposure to pesticides
  • Living in an area with poor air quality or pollutants
  • After puberty, sex hormones may play a role, with girls being 2 times more likely to develop pediatric MS than boys

  • Obesity

Genes can also play a role. For example, researchers have identified the HLA allele (or gene variation) that raises the risk of pediatric MS. A combination of genetic predisposition and exposure to certain environmental factors is likely what drives MS.

How Is Pediatric MS Diagnosed?

Just like in adults, diagnosing MS in children is a complex process involving a discussion of symptoms and when they occurred, a basic neurological exam, and tests both to look for signs of MS and to rule out other things such as infection, vitamin deficiencies, and other conditions that mimic MS.

Tests that a doctor may order include:

  • Blood tests
  • An MRI scan
  • A spinal tap, also called a lumbar puncture
  • An evoked potentials test, which is a noninvasive procedure where tiny electrodes are attached to the head while your child receives visual or auditory stimuli

The Challenges of Diagnosing Pediatric MS

MS in children often goes undiagnosed because pediatricians sometimes miss the condition in their patients and are unfamiliar with the signs and symptoms.

“Also, adolescents sometimes aren’t forthcoming about their symptoms, and parents can be slow to recognize the problem,” says Dr. Krupp. “In general, the younger the child, the harder the diagnosis.”

“There are several diagnoses that look very much like MS but may respond to different medicines than MS,” says Dr. Yeh. “The most important thing is that your child’s care team thinks broadly when encountering a young person with new brain lesions that look inflammatory.”

Diagnosing MS vs. Other Conditions

Diagnosing MS in children is more challenging than it is in adults because it is often confused with other disorders with similar symptoms and characteristics that are more common in young people, such as acute disseminated encephalomyelitis (ADEM) or clinically isolated syndrome (CIS).

Pediatric MS vs. ADEM

Acute disseminated encephalomyelitis is a brief but intense attack of inflammation in the CNS (the brain and spinal cord) that, like MS, causes damage to the myelin sheaths that protect nerve cells. The condition is sometimes called post-infectious encephalomyelitis or immune-mediated encephalomyelitis. In most cases of ADEM, symptoms occur within two weeks of a viral or bacterial infection.

As in MS, common symptoms of ADEM include vision loss, muscle numbness and weakness, and balance or coordination problems. Unlike MS, however, ADEM is monophasic: It occurs once without recurring later, whereas MS has relapses or progression.

Pediatric MS vs. CIS

Clinically isolated syndrome is an initial occurrence of neurologic symptoms lasting at least 24 hours, caused by inflammation or demyelination in the CNS. People who experience CIS may later develop MS.

Pediatric MS vs. Other Conditions

Some other conditions that can cause symptoms similar to MS and that may need to be ruled out when diagnosing a child include:

Treatment and Medication Options for Pediatric MS

To date, there’s only one disease-modifying therapy (DMT) approved in the United States for use in children with MS: the oral drug fingolimod (Gilenya).

The U.S. Food and Drug Administration (FDA) has approved its use for treating pediatric MS in children and adolescents age 10 or older.

In MS, which is an autoimmune condition, your immune system mistakenly attacks the nerve cells in your CNS. Fingolimod is an immunosuppressant that is thought to work by keeping your body’s immune cells in your lymph nodes, where they can’t attack the CNS.

Off-label Use of DMTs for Pediatric MS

Oral DMTs used off-label in children with relapsing-remitting MS include:

  • dimethyl fumarate (Tecfidera)
  • teriflunomide (Aubagio)
  • alemtuzumab (Lemtrada)
  • natalizumab (Tysabri)
  • rituximab (Rituxan)

  • glatiramer acetate (Copaxone)
  • interferon beta (Avonex, Rebif, Plegridy)
Some of these drugs are currently being evaluated in clinical trials involving pediatric patients with the condition, and some are already approved in other countries outside the United States.

Options for Treating MS Relapses

During MS flares, high-dose corticosteroids may be prescribed to reduce inflammation in the CNS. The most commonly used corticosteroid in children with MS is methylprednisolone, which is administered intravenously once a day for three to five days.

Your child’s doctor may also prescribe prednisone, another corticosteroid, which is available in pill form. It’s typically used for a short time following IV methylprednisolone administration.

Although most children generally tolerate corticosteroids well, they may experience some side effects, such as:

  • Behavior changes
  • Increases in blood sugar levels
  • Nausea

Other options for treating relapse include plasma exchange and intravenous immunoglobulin (IVIG). Plasma exchange, also called plasmapheresis or PLEX, essentially removes the antibodies in the blood that attack myelin in the nerve cells of people with MS. Several treatments are given over a couple of weeks.

IVIG is an IV medication composed of antibodies from healthy blood donors and helps reduce the immune response in MS. IVIG is not typically the first treatment used for an MS relapse but may be used in certain situations.

Additional Parts of the MS Treatment Plan

Any treatment plan for children with MS should also include:

  • Physical therapy
  • Occupational therapy
  • Speech therapy

These can help improve mobility, muscle strength, and balance and coordination.

It’s important to remember that children diagnosed with MS can experience emotional and social challenges. Having a chronic condition like MS can affect a young person’s self-confidence, academic performance, peer relationships, family and social life, and overall behavior.

It may also impact how they view their lives, both in the present and in the future.

Thus, Krupp says, it’s vital that children with MS communicate regularly with school counselors, therapists, and others who can help them with these challenges. Encourage them to talk about their experiences and problems, and make sure they get support from teachers, family, friends, and other members of the community.

“A team that provides counseling, ideally peer-based support programs, is key," she says.

Yeh adds that a comprehensive program should address all the needs of children with MS, and ideally should include physicians, nurses, nurse practitioners, social workers, psychologists, neuropsychological assessment, and physiotherapists and occupational therapists, among other healthcare workers.

Ultimately, planning your child’s MS treatment should include discussing the goals and expectations of the child and the family, as well as any potential risks. Children on DMTs and other prescription medication should also undergo routine monitoring (including blood tests, MRIs, and other tests) to make sure the treatment is working and to minimize side effects.

Lifestyle Changes for Pediatric MS

Managing emotional and social challenges, and sticking to a healthy lifestyle with an appropriate diet and physical activity, are key parts of maintaining a good quality of life well into adulthood. "It’s critical that kids exercise, stay engaged with friends, and participate fully in school,” says Krupp.

Maintaining a healthy body weight and keeping active are also important, Yeh adds. “Exercise physiologists, nutritionists, and dietitians can help us when needed. Social workers and nursing staff play important roles in the care of families of children with MS as well.”

Prognosis and Outlook

The exact outlook for a child with MS is difficult to predict. But it’s important to remember that MS doesn’t shorten a child’s lifespan and, as Krupp emphasizes, many pediatric patients with MS have grown up to have successful careers and start their own families.

“We’re still learning about long-term outcomes with pediatric MS, but I like to be optimistic, as our therapies are better than before,” Krupp adds. “I have many patients in their mid-thirties who are doing well and have had MS since their early teens.”

Possible Complications of Pediatric MS

Children with MS often experience psychosocial and cognitive complications, including:

  • Mood disorders
  • Cognitive impairment
  • Anxiety
  • Depression
  • Difficulty socializing

With the right support and comprehensive care, many, if not all of these complications can be avoided.

Due to the early onset of the illness, there is also a risk that children with MS will go on to develop physical disability by the time they reach early adulthood.

However, it’s important to note that due to advancements in new therapies, these negative outcomes may be offset.

Disparities in Pediatric MS

Generally speaking, MS is diagnosed disproportionately more in white people of European descent.

 However, the prevalence of this illness among Black patients is on the rise, which may suggest changes in the environment, genes, and diagnosis.

The illness also tends to be more severe when it’s diagnosed in Black Americans than in white Americans, which could mean that MS was historically under-recognized and under-diagnosed in this population.

Regarding pediatric MS specifically, more and more Hispanic children are being diagnosed with the condition, and they tend to develop the illness earlier on than their white counterparts.

Black children with MS tend to relapse at a higher rate than white children. They also tend to perform less well on language and complex attention tasks than their white peers with MS, presumably as a result of social disparities that put Black MS patients at a disadvantage and a healthcare system that underserves them.

A lower socioeconomic level, independent of race or ethnicity, has also been shown to increase the risk of developing MS.

Support for Children With MS

Your child’s MS healthcare providers are a good place to start to find peer support resources in your area. And, to help you when you accompany your child to their healthcare appointments, consider using TheKidsDoc app from the American Academy of Pediatrics (AAP).

For summertime fun and learning, the National MS Society holds adventure camps for young people with MS in grades 4 through 12 who live in a household with someone affected by MS. In 2021, they offered virtual adventure camps for teens ages 13 to 17 who have a parent with MS.

The NMSS also operates online support groups for kids, teens, and people in their twenties, such as The MS Youngsters Group, or the Parents of Children and Young Adults With MS Group. They also have a useful online directory of support groups to help you find one in your area.

The Takeaway

  • Adults are not the only ones diagnosed with MS. Children can develop MS too.
  • The vast majority of pediatric MS cases are the relapsing-remitting form of the condition (RRMS).
  • Although pediatric MS cannot be prevented or cured, it can be managed through a combination of DMTs, lifestyle changes, and a comprehensive care plan. Many kids with MS go on to live happy, fulfilling lives into their adulthood.
  • Reach out to your healthcare provider for helpful resources and support.
EDITORIAL SOURCES
Everyday Health follows strict sourcing guidelines to ensure the accuracy of its content, outlined in our editorial policy. We use only trustworthy sources, including peer-reviewed studies, board-certified medical experts, patients with lived experience, and information from top institutions.
Resources
  1. Pediatric Multiple Sclerosis. National Multiple Sclerosis Society.
  2. Types of Multiple Sclerosis. Multiple Sclerosis Association of America. July 12, 2024.
  3. Types of MS. MS Society.
  4. Childhood MS. Multiple Sclerosis Trust. July 19, 2019.
  5. Pediatric Multiple Sclerosis. Children’s Hospital of Philadelphia.
  6. Pediatric MS. National Multiple Sclerosis Society.
  7. Brenton JN et al. Multiple Sclerosis in Children: Current and Emerging Concepts. Seminars in Neurology. April 15, 2020.
  8. Which Children Get MS? International Pediatric MS Study Group (IPMSSG).
  9. Diagnosing Childhood MS. Multiple Sclerosis Trust.
  10. Drug Information. Pediatric Multiple Sclerosis Alliance.
  11. Gilenya (fingolimod) Information for Healthcare Professionals. Novartis Pharmaceuticals Corporation.
  12. Waubant E et al. Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG. Neurology. May 28, 2019.
  13. Śladowska K et al. Efficacy and safety of disease-modifying therapies in pediatric-onset multiple sclerosis: A systematic review of clinical trials and observational studies. Multiple Sclerosis and Related Disorders. February 2025.
  14. Etemadifar M et al. Anti-CD20 therapies for pediatric-onset multiple sclerosis: A systematic review. Multiple Sclerosis and Related Disorders. August 31, 2024.
  15. Childhood MS: A Guide for Parents. Multiple Sclerosis International Federation (MSIF).
  16. Multiple Sclerosis (MS). Boston Children's Hospital.
  17. Brola W et al. Paediatric multiple sclerosis — current diagnosis and treatment. Neurologia i Neurochirurgia Polska (Polish Journal of Neurology and Neurosurgery). 2020.
  18. Waldman A et al. Pediatric multiple sclerosis: Clinical features and outcome. Neurology. August 30, 2016.
  19. Amezcua L et al. Race and Ethnicity on MS presentation and Disease Course: ACTRIMS Forum 2019. Multiple Sclerosis. January 22, 2020.
  20. Poisson KE et al. Impact of race and socioeconomic deprivation on clinical outcomes and healthcare utilization in pediatric multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical. August 26, 2024.
  21. Ross R et al. Association of Social Determinants of Health With Brain MRI Outcomes in Individuals With Pediatric Onset Multiple Sclerosis. Neurology. November 27, 2024.
  22. Jensen SKG et al. Early Adversity and Socioeconomic Factors in Pediatric Multiple Sclerosis. Neurology Neuroimmunology & Neuroinflammation. August 15, 2024.
jason-paul-chua-bio

Jason Paul Chua, MD, PhD

Medical Reviewer

Jason Chua, MD, PhD, is an assistant professor in the Department of Neurology and Division of Movement Disorders at Johns Hopkins School of Medicine. He received his training at the University of Michigan, where he obtained medical and graduate degrees, then completed a residency in neurology and a combined clinical/research fellowship in movement disorders and neurodegeneration.

Dr. Chua’s primary research interests are in neurodegenerative disease, with a special focus on the cellular housekeeping pathway of autophagy and its impact on disease development in diseases such as Parkinson disease. His work has been supported by multiple research training and career development grants from the National Institute of Neurological Disorders and Stroke and the American Academy of Neurology. He is the primary or coauthor of 14 peer-reviewed scientific publications and two peer-reviewed online learning modules from the American Academy of Neurology. He is also a contributing author to The Little Black Book of Neurology by Osama Zaldat, MD and Alan Lerner, MD, and has peer reviewed for the scientific journals Autophagy, eLife, and Neurobiology of Disease.

Brian P. Dunleavy

Author

Brian P. Dunleavy is a writer and editor with more than 25 years of experience covering issues related to health and medicine for both consumer and professional audiences. As a journalist, his work has focused on new research in the treatment of infectious diseases, neurological disorders (including multiple sclerosis and Alzheimer's disease), and pain management. His work has appeared in ADDitude, Consumer Reports, Health, Pain Medicine News, and Clinical Oncology News.

Dunleavy is the former editor of the infectious disease special edition at ContagionLive.com. He is also an experienced sports reporter who has covered the NFL, MLB, NBA, NHL, and professional soccer for a number of publications. He is based in New York City.

Ana Sandoiu

Author

Ana is a freelance medical copywriter, editor, and health journalist with a decade of experience in content creation. She loves to dive deep into the research and emerge with engaging and informative content everyone can understand. Her strength is combining scientific rigor with empathy and sensitivity, using conscious, people-first language without compromising accuracy.

Previously, she worked as a news editor for Medical News Today and Healthline Media. Her work as a health journalist has reached millions of readers, and her in-depth reporting has been cited in multiple peer-reviewed journals. As a medical copywriter, Ana has worked with award-winning digital agencies to implement marketing strategies for high-profile stakeholders. She’s passionate about health equity journalism, having conceived, written, and edited features that expose health disparities related to race, gender, and other social determinants of health.

Outside of work, she loves dancing, taking analog photos, and binge-watching all the RuPaul’s Drag Race franchises.